Novartis ( Novartis )


Novartis's picture

About Novartis

We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.

Novartis press release, blog etc

11/05/2018 - 08:29 Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
11/01/2018 - 23:01 Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
11/01/2018 - 21:57 Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
10/31/2018 - 06:38 Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
10/29/2018 - 03:17 Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
10/27/2018 - 06:46 Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
10/26/2018 - 05:17 Novartis receives approval for Cosentyx label update in Europe to include dosing flexibility in psoriatic arthritis
10/23/2018 - 07:47 Alcon to develop SMART Suite digital health platform for cataract surgery
10/23/2018 - 07:47 Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
10/22/2018 - 04:34 Novartis COMBI-AD study of Tafinlar + Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
10/20/2018 - 16:56 Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
10/19/2018 - 07:27 Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
10/19/2018 - 06:50 Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
10/18/2018 - 11:35 Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
10/16/2018 - 12:45 Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
10/11/2018 - 19:51 Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
10/10/2018 - 20:29 Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
10/09/2018 - 20:14 Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis